Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biofrontera Inc. stock logo
BFRI
Biofrontera
$0.95
-0.4%
$0.79
$0.54
$2.22
$9.60M0.592,391 shs30,044 shs
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
$0.88
+4.8%
$1.20
$0.72
$5.66
$10.73M0.93188,481 shs147,712 shs
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
$3.10
$3.10
$2.50
$13.00
$10.58M2.352,472 shsN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
$1.16
-0.9%
$1.84
$1.06
$12.50
$2.67M4.181.44 million shs110,654 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biofrontera Inc. stock logo
BFRI
Biofrontera
0.00%-8.99%+10.06%+38.68%-27.75%
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
0.00%-0.51%-26.01%-34.29%-81.27%
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.00%0.00%0.00%0.00%0.00%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
0.00%-3.33%-47.03%-42.00%-99.56%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biofrontera Inc. stock logo
BFRI
Biofrontera
1.5147 of 5 stars
3.53.00.00.00.00.00.6
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
2.8365 of 5 stars
3.25.00.00.01.12.50.6
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biofrontera Inc. stock logo
BFRI
Biofrontera
3.00
Buy$2.75190.54% Upside
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
2.33
Hold$4.50411.07% Upside
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.00
N/AN/AN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest RDHL, HOOK, PHXM, and BFRI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Biofrontera Inc. stock logo
BFRI
Biofrontera
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$7.00 ➝ $2.75
(Data available from 8/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biofrontera Inc. stock logo
BFRI
Biofrontera
$38.00M0.25N/AN/A$0.57 per share1.66
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
$9.35M1.15N/AN/A$4.25 per share0.21
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
N/AN/AN/AN/A$7.98 per shareN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
$8.04M0.33N/AN/A($3.66) per share-0.32
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biofrontera Inc. stock logo
BFRI
Biofrontera
-$17.76M-$2.26N/AN/AN/A-30.33%-305.13%-82.67%8/13/2025 (Estimated)
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
-$43.50M-$5.85N/AN/AN/A-785.66%-120.09%-77.14%8/14/2025 (Estimated)
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
-$240KN/A0.00N/AN/AN/AN/AN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
-$8.27MN/A0.00N/AN/AN/AN/AN/A

Latest RDHL, HOOK, PHXM, and BFRI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
-$0.64N/AN/AN/AN/AN/A
8/13/2025Q2 2025
Biofrontera Inc. stock logo
BFRI
Biofrontera
-$0.45N/AN/AN/A$8.30 millionN/A
5/15/2025Q1 2025
Biofrontera Inc. stock logo
BFRI
Biofrontera
-$0.14-$0.47-$0.33-$0.47$10.55 million$8.59 million
5/15/2025Q1 2025
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
-$0.61-$1.23-$0.62-$1.23$3.38 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biofrontera Inc. stock logo
BFRI
Biofrontera
N/AN/AN/AN/AN/A
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
N/AN/AN/AN/AN/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
N/AN/AN/AN/AN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biofrontera Inc. stock logo
BFRI
Biofrontera
8.99
1.40
0.80
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
N/A
3.61
3.61
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.23
1.78
N/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
N/A
0.54
0.37

Institutional Ownership

CompanyInstitutional Ownership
Biofrontera Inc. stock logo
BFRI
Biofrontera
10.08%
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
63.88%
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.40%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
7.20%

Insider Ownership

CompanyInsider Ownership
Biofrontera Inc. stock logo
BFRI
Biofrontera
1.20%
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
3.30%
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
1.94%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
6.81%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biofrontera Inc. stock logo
BFRI
Biofrontera
7010.14 million9.65 millionNo Data
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
16012.19 million11.79 millionOptionable
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
493.41 million3.35 millionNo Data
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
2102.30 million2.14 millionNo Data

Recent News About These Companies

RedHill Biopharma Ltd. (RDHL) - Yahoo Finance
RedHill Biopharma receives non-compliance letter from Nasdaq
RedHill Biopharma announces publication in journal on Opaganib
RedHill Biopharma to submit UK MAA for Talicia
RedHill to file FDA-approved Talicia for UK marketing

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biofrontera stock logo

Biofrontera NASDAQ:BFRI

$0.95 0.00 (-0.37%)
Closing price 08/8/2025 03:59 PM Eastern
Extended Trading
$0.95 +0.01 (+0.69%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

HOOKIPA Pharma stock logo

HOOKIPA Pharma NASDAQ:HOOK

$0.88 +0.04 (+4.78%)
As of 08/8/2025 03:47 PM Eastern

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

PHAXIAM Therapeutics stock logo

PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)
As of 08/8/2025

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Redhill Biopharma stock logo

Redhill Biopharma NASDAQ:RDHL

$1.16 -0.01 (-0.85%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$1.19 +0.03 (+2.59%)
As of 08:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.